ZALTRAP, also known by its generic name aflibercept, is a biopharmaceutical medication primarily used in the treatment of metastatic colorectal cancer, specifically in patients whose cancer has progressed after receiving other chemotherapy treatments. It functions as an angiogenesis inhibitor, which means it works by blocking the growth of new blood vessels that tumors need to grow and spread. ZALTRAP is typically administered in combination with a regimen of other chemotherapy drugs, such as FOLFIRI (folinic acid, fluorouracil, and irinotecan), to enhance its effectiveness. It is administered intravenously and is part of a class of drugs known as antineoplastic agents. By targeting vascular endothelial growth factors (VEGF), ZALTRAP helps to slow down the growth and spread of cancer cells, offering a therapeutic option for patients with advanced stages of colorectal cancer.